These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30378704)

  • 1. Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features.
    Yasin SA; Schutz PW; Deakin CT; Sag E; Varsani H; Simou S; Marshall LR; Tansley SL; McHugh NJ; Holton JL; Wedderburn LR; Jacques TS;
    Neuropathol Appl Neurobiol; 2019 Aug; 45(5):495-512. PubMed ID: 30378704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
    Merlonghi G; Antonini G; Garibaldi M
    Autoimmun Rev; 2022 Feb; 21(2):102993. PubMed ID: 34798316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.
    Nguyen M; Do V; Yell PC; Jo C; Liu J; Burns DK; Wright T; Cai C
    Acta Neuropathol Commun; 2020 Aug; 8(1):125. PubMed ID: 32758284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
    Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
    Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.
    Rider LG; Shah M; Mamyrova G; Huber AM; Rice MM; Targoff IN; Miller FW;
    Medicine (Baltimore); 2013 Jul; 92(4):223-243. PubMed ID: 23877355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
    Mariampillai K; Granger B; Amelin D; Guiguet M; Hachulla E; Maurier F; Meyer A; Tohmé A; Charuel JL; Musset L; Allenbach Y; Benveniste O
    JAMA Neurol; 2018 Dec; 75(12):1528-1537. PubMed ID: 30208379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies.
    Xu Q; Li QX; Bi FF; Duan HQ; Luo YB; Yang H
    Clin Rheumatol; 2021 Feb; 40(2):613-624. PubMed ID: 32671659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis.
    Mescam-Mancini L; Allenbach Y; Hervier B; Devilliers H; Mariampillay K; Dubourg O; Maisonobe T; Gherardi R; Mezin P; Preusse C; Stenzel W; Benveniste O
    Brain; 2015 Sep; 138(Pt 9):2485-92. PubMed ID: 26198592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Muscle Biopsy Features with Myositis Autoantibodies in Inflammatory Myopathies: A Pilot Experience.
    Gudipati A; Rifat S; Uppin M; Jabeen A; Mathukumalli NL; Yareeda S; Kayidhi S; Pyal A; Dhamne M; Reddy YM
    Ann Indian Acad Neurol; 2023; 26(4):408-418. PubMed ID: 37970294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling.
    Melki I; Devilliers H; Gitiaux C; Bondet V; Duffy D; Charuel JL; Miyara M; Bokov P; Kheniche A; Kwon T; Authier FJ; Allenbach Y; Belot A; Bodemer C; Bourrat E; Dumaine C; Fabien N; Faye A; Frémond ML; Hadchouel A; Kitabayashi N; Lepelley A; Martin-Niclos MJ; Mudumba S; Musset L; Quartier P; Rice GI; Seabra L; Uettwiller F; Uggenti C; Viel S; Rodero MP; Crow YJ; Bader-Meunier B
    Rheumatology (Oxford); 2020 Aug; 59(8):1927-1937. PubMed ID: 31755959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.
    Rider LG; Nistala K
    J Intern Med; 2016 Jul; 280(1):24-38. PubMed ID: 27028907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.
    Shah M; Mamyrova G; Targoff IN; Huber AM; Malley JD; Rice MM; Miller FW; Rider LG;
    Medicine (Baltimore); 2013 Jan; 92(1):25-41. PubMed ID: 23263716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological features of systemic sclerosis-associated myopathy: A scoping review.
    Lefebvre F; Giannini M; Ellezam B; Leclair V; Troyanov Y; Hoa S; Bourré-Tessier J; Satoh M; Fritzler MJ; Senécal JL; Hudson M; Meyer A; Landon-Cardinal O
    Autoimmun Rev; 2021 Jul; 20(7):102851. PubMed ID: 33971337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.
    Tansley SL; Betteridge ZE; Gunawardena H; Jacques TS; Owens CM; Pilkington C; Arnold K; Yasin S; Moraitis E; Wedderburn LR; McHugh NJ;
    Arthritis Res Ther; 2014 Jul; 16(4):R138. PubMed ID: 24989778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study.
    Yamasaki Y; Kobayashi N; Akioka S; Yamazaki K; Takezaki S; Nakaseko H; Ohara A; Nishimura K; Nishida Y; Sato S; Kishi T; Hashimoto M; Mori M; Okazaki Y; Kuwana M; Ohta A
    Rheumatology (Oxford); 2021 Oct; 60(10):4821-4831. PubMed ID: 33576399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort.
    Loganathan A; Gupta L; Rudge A; Lu H; Bowler E; McMorrow F; Naveen R; Anuja AK; Agarwal V; McHugh N; Tansley S
    Rheumatology (Oxford); 2024 Sep; 63(9):2363-2371. PubMed ID: 38479813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.
    Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG
    Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.
    Betteridge Z; Tansley S; Shaddick G; Chinoy H; Cooper RG; New RP; Lilleker JB; Vencovsky J; Chazarain L; Danko K; Nagy-Vincze M; Bodoki L; Dastmalchi M; Ekholm L; Lundberg IE; McHugh N;
    J Autoimmun; 2019 Jul; 101():48-55. PubMed ID: 30992170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.
    Srivastava P; Dwivedi S; Misra R
    Rheumatol Int; 2016 Jul; 36(7):935-43. PubMed ID: 27193471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies.
    Perron MM; Vasquez-Canizares N; Tarshish G; Wahezi DM
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):92. PubMed ID: 34118936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.